Get started
Author

Shanzhi Gu

Observed names: S Gu, S. Gu
ORCID: 0009-0003-7599-1208
Observed ORCID: 0009-0003-7599-1208
OpenAlex ID: A5088645687
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · Bruno Sangro, Masatoshi Kudo, et al. · The Lancet · 389
PDF
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
2022 · S. Qin, L.S. Chan, et al. · Annals of Oncology · 98
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
2025 · Yinghong Shi, Guohong Han, et al. · The Lancet. Gastroenterology & hepatology · 66
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2023 · Chunhui Zhou, Yan Li, et al. · Clinical Cancer Research · 25
SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.
2024 · Jianming Xu, Yanqiao Zhang, et al. · Journal of Clinical Oncology · 16
Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
2025 · Jia Fan, Jian Zhou, et al. · Journal of Clinical Oncology · 7
PDF
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
2024 · Shengxiang Ren, Anwen Xiong, et al. · Cancer Immunology Immunotherapy · 7
Abstract CT168: EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an international phase Ib/II study
2025 · Lin Shen, Christine M. Parseghian, et al. · Cancer Research · 2
First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.
2025 · Feng Bi, Yanqiao Zhang, et al. · Journal of Clinical Oncology · 2
43P Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
2023 · S. Ren, X. Wang, et al. · Journal of Thoracic Oncology · 1
PDF
Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2025 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2025 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 3 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2025 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2025 · Chunhui Zhou, Yan Li, et al.
Supplementary Data 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2025 · Chunhui Zhou, Yan Li, et al.
Supplementary Data 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 3 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2024 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 2 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2023 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 3 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2023 · Chunhui Zhou, Yan Li, et al.
Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2023 · Chunhui Zhou, Yan Li, et al.
Supplementary Data 1 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
2023 · Chunhui Zhou, Yan Li, et al.
Works count: 38
Citation count: 613
H-index: 7
I10-index: 5
Year
Topic
Type